Sislax Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 5.00 M
as on 16-11-2024
- Company Age 29 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 13.65 Cr
as on 16-11-2024
- Satisfied Charges ₹ 4.29 Cr
as on 16-11-2024
- Revenue 10.15%
(FY 2023)
- Profit 145.03%
(FY 2023)
- Ebitda 229.83%
(FY 2023)
- Net Worth 7.73%
(FY 2023)
- Total Assets -4.45%
(FY 2023)
About Sislax Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹13.65 Cr. The company has closed loans amounting to ₹4.29 Cr, as per Ministry of Corporate Affairs (MCA) records.
Usha Vig, Sunanda Gupta, and Satish Bamba serve as directors at the Company.
- CIN/LLPIN
U24232CH1995PTC016300
- Company No.
016300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationUt, Chandigarh
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sislax Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunanda Gupta  | Director | 02-Feb-2015 | Current |
| Usha Vig | Director | 12-Jun-2006 | Current |
| Satish Bamba | Director | 31-Oct-2017 | Current |
Financial Performance of Sislax Pharma.
Sislax Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.15% increase. The company also saw a substantial improvement in profitability, with a 145.03% increase in profit. The company's net worth moved up by a moderate rise of 7.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sislax Pharma?
In 2023, Sislax Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jun 2024 | ₹8.00 Cr | Open |
Others Creation Date: 14 May 2012 | ₹5.65 Cr | Open |
Canara Bank Creation Date: 02 Mar 2005 | ₹3.40 Cr | Satisfied |
How Many Employees Work at Sislax Pharma?
Sislax Pharma has a workforce of 24 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sislax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sislax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
